Ichikawa, Tomotsugu <br/><br/>
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.  [electronic resource] 

 -  Clinical neurology and neurosurgery  Dec 2014 
 - 106-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-6968 
<br/><br/><label>Standard No.: </label>10.1016/j.clineuro.2014.10.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Central Nervous System Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Karnofsky Performance Status<br/>Lymphoma--drug therapy<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Neuropsychological Tests<br/>Prednisolone--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--administration & dosage